Yu H, Schreiber SL. Signalling an interest. Nat Struct Biol. 1994;1(7):417-20.
Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature. 1995;377(6548):441-6. doi:10.1038/377441a0
Wilson AJ, Holson E, Wagner F, et al. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biol Ther. 2011;12(6):484-93. doi:10.4161/cbt.12.6.15956
Luo T, Masson K, Jaffe JD, et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A. 2012;109(8):2860-5. doi:10.1073/pnas.1120589109
Schreiber SL, Bernstein BE. Signaling network model of chromatin. Cell. 2002;111(6):771-8.
Pflum MK, Tong JK, Lane WS, Schreiber SL. Histone deacetylase 1 phosphorylation promotes enzymatic activity and complex formation. J Biol Chem. 2001;276(50):47733-41. doi:10.1074/jbc.M105590200
Nghiem P, Park PK, Ys Y son K, Desai BN, Schreiber SL. ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint. J Biol Chem. 2002;277(6):4428-34. doi:10.1074/jbc.M106113200
MacBeath G, Schreiber SL. Printing proteins as microarrays for high-throughput function determination. Science. 2000;289(5485):1760-3.
Shamji AF, Nghiem P, Schreiber SL. Integration of growth factor and nutrient signaling: implications for cancer biology. Mol Cell. 2003;12(2):271-80.
Yang J, Shamji A, Matchacheep S, Schreiber SL. Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening. Chem Biol. 2007;14(4):371-7. doi:10.1016/j.chembiol.2007.02.004